相关临床试验
170
86 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1883
进行中（未招募）
85
50.0%
已完成
63
37.1%
尚未招募
1
0.6%
招募中
5
2.9%
暂停
1
0.6%
终止
4
2.4%
Unknown
9
5.3%
撤回
2
1.2%
暂无批准数据
- Amateur soccer players who headed the ball showed significantly higher immediate increases in S100B and p-tau217 blood biomarkers compared to non-heading players, according to a JAMA Neurology study. - A clear dose-response relationship emerged: more headers and high-impact headers (ball trajectory >20 meters) correlated with larger biomarker elevations. - Biomarker levels normalized within 24–48 hours post-match, though researchers caution the long-term consequences for brain health remain uncertain. - The prospective study of 302 adult male players suggests even amateur-level heading may acutely affect neural integrity, warranting further research in women, children, and professionals.
- Harness Therapeutics has nominated HRN001, a first-in-class antisense oligonucleotide targeting FAN1 nuclease, as its lead drug candidate for Huntington's disease treatment. - The company established a clinical advisory board comprising seven leading Huntington's disease experts to guide HRN001's progression toward first-in-human studies planned for 2027. - HRN001 leverages Harness' proprietary MISBA® platform to precisely upregulate FAN1 protein levels, addressing somatic expansion which drives Huntington's disease progression. - Preclinical studies demonstrate that HRN001 achieves robust FAN1 upregulation and slows somatic expansion in Huntington's disease models while showing favorable pharmacokinetic and tolerability profiles.
- The NHS has launched GlobalMinds, the world's largest mental health study, recruiting 49,000 participants with severe mental illness including schizophrenia, bipolar disorder, and major depression to develop personalized treatments. - The three-year study combines genetic data from blood or saliva samples with questionnaire responses and NHS medical records to create the most detailed dataset on serious mental health conditions. - Researchers aim to transform understanding of severe mental illness and unlock precision medicine approaches similar to those that have revolutionized cancer treatment. - The study is supported by 10 NHS trusts and led by Akrivia Health in partnership with Cardiff University, with funding from the Wellcome Trust and Johnson & Johnson.
- Draig Therapeutics received FDA clearance for its IND application to initiate a Phase 2 study of DT-101, a next-generation AMPA receptor positive allosteric modulator for major depressive disorder. - The TARIAN-1 study will be a multi-center, randomized, double-blind, placebo-controlled trial enrolling more than 300 participants with MDD, with topline data expected in the second half of 2027. - The Phase 2 trial builds on positive Phase 1 results in over 60 subjects where DT-101 demonstrated good tolerability and target engagement using magnetoencephalography. - The company raised $140 million in Series A funding in June 2025 to advance DT-101 and two additional GABAA receptor modulators into clinical development.
- Draig Therapeutics launched with $140 million in Series A funding to develop next-generation treatments for neuropsychiatric disorders, marking the largest commercial investment in Welsh research to date. - The company's lead candidate DT-101, an AMPA receptor positive allosteric modulator for major depressive disorder, will enter Phase 2 trials in 2025 following successful Phase 1 results in over 60 subjects. - Founded by Cardiff University professors targeting glutamate and GABA neurotransmitter pathways, Draig aims to address significant unmet medical needs in neuropsychiatric conditions with improved safety profiles. - The funding round was led by Access Biotechnology with participation from major investors including Canaan Partners, SR One, and Sanofi Ventures, supporting advancement of multiple pipeline candidates.
- A groundbreaking UK trial has developed a highly sensitive bone marrow test that can detect returning Acute Myeloid Leukemia up to three months earlier than standard blood tests, potentially doubling survival rates for some patients. - The test identifies minimal residual disease in patients' bone marrow while they are still in clinical remission, creating a crucial window of opportunity for intervention before patients become symptomatic. - Researchers from King's College London are now working with the NHS to implement the 10-minute procedure as standard care across the UK, with potential applications for other cancer types.
- The API-CAT trial demonstrated that reduced-dose apixaban (2.5mg twice daily) was noninferior to full-dose (5mg twice daily) for preventing recurrent venous thromboembolism in cancer patients requiring extended anticoagulation. - Patients receiving the lower dose experienced significantly fewer bleeding events (12.1% vs 15.6%) while maintaining similar protection against blood clots, potentially changing clinical practice guidelines for cancer-associated thrombosis management. - The findings are particularly significant as cancer patients live longer with improved treatments but face ongoing thrombosis risks, offering clinicians a safer option for long-term anticoagulation beyond the initial 6-month treatment period.
- A clinical trial found that ustekinumab, a drug currently used for psoriasis, preserved insulin production in young type 1 diabetes patients, with C-peptide levels 49% higher after one year compared to placebo. - Researchers discovered ustekinumab targets a specific subset of immune cells called Th17.1 cells, which make up only 0.1% of blood immune cells but play a key role in destroying insulin-producing cells. - The treatment could potentially reduce or eliminate the need for insulin injections if administered early enough, with researchers suggesting future trials combining screening and early intervention.
